ELOX - Company ID 0001035354
The table below shows Eloxx Pharmaceuticals, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $2.84M | - | $898.00K | - | - | - |
| SG&A |
Eloxx Pharmaceuticals, Inc. reported annual revenue of $0.00 for fiscal year 2025. That is down 100.0% from $6.36M in fiscal 2024. Over the 7 fiscal years shown, annual revenue declined from $140.00K (FY 2010) to $0.00. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $1.61M |
| $2.14M |
| $684.00K |
| $712.00K |
| $2.39M |
| $1.80M |
| Operating income | -$4.45M | -$3.79M | -$1.58M | -$1.22M | -$3.64M | -$4.14M |
| Income tax | - | - | - | - | - | - |
| Net income | -$4.50M | -$3.75M | -$1.89M | -$1.71M | -$3.59M | -$4.34M |
| EPS (diluted) | -$0.66 | -$0.86 | -$5.45 | -$4.94 | -$1.31 | -$1.96 |